This article published in Nature Biotechnology asks the question "Will your orphan drug startup draw acquisition interest?"
Authored by Forbion General Partner Rogier Rooswinkel, Forbion Managing Partner Geert-Jan Mulder & Forbion Operating Partner Sander van Deventer.